Once stigmatized across the western world, the likes of MDMA, LSD and magic mushrooms are taking back their place in the world of medicine. Recreational wellness startups have begun to pop up, too. But the industry is crying out for a repositioning.
"It is very clear that psychedelics need to be regulated by the FDA, and I believe MindMed has both the team and strategy to conduct the necessary trials and create next-generation psychedelics.” said MindMed Investor and Board Member Bruce Linton
Investors in the latest round include Kevin O'Leary, Bruce Linton, the former CEO of the world's biggest cannabis grower, Canopy Growth, and James Bailey, a partner at private equity firm Bail Capital and early investor in psychedelics company Compass Pathways.
New York, NY -- June 26, 2020-- MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on March 3, 2020.
Basel, Switzerland June 24, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing technologies and analytics that seek to personalize psychedelic therap
Basel, Switzerland June 18, 2020 // Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials
Basel, Switzerland, June 8, 2020 /PRNewswire/ Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB:MMEDF), is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab.
New York, NY, June 4, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, has officially launched Project Lucy, a commercial drug development program for the treat